(Press release, Epizyme, OCT 14, 2011, View Source [SID:1234503836])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 13, 2011 Cancer Research Technology – the commercial arm of Cancer Research UK – reported the appointment of Peter Chambré as its new chairman (Press release, Cancer Research Technology, OCT 13, 2011, View Source [SID1234523319]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Peter is currently chairman of two private equity-backed pharmaceutical businesses, Xellia Pharmaceuticals and 7TM Pharma and he is a non-executive director of BTG plc and Spectris plc. From 2002 until 2006, Peter was Chief Executive of Cambridge Antibody Technology Group plc.

He succeeds Melanie Lee who has been chairman of CRT since 2003.

Michael Pragnell, chairman of Cancer Research UK, said: "We’re delighted to welcome Peter Chambré who will be bringing extremely valuable industry experience to the Board, as CRT is seeking to create new partnerships between industry and academia.

"I’d like to thank Melanie Lee for her exceptional contribution to CRT and as a former Trustee of Cancer Research UK. We wish her all the best for the future."

(Press release, Ligand, OCT 10, 2011, View Source [SID:1234503856])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A few years ago Tolerx would have been an unlikely company to appear in this report (External Source FierceBiotech , Tolerx, OCT 7, 2011, View Source [SID:1234501045]). Its monoclonal antibody for type 1 diabetes, called otelixizumab, helped the company land a rich pact in 2007 with GlaxoSmithKline worth $760 million. The deal included $70 million in upfront cash.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two parteners headed in to Phase III trials with high expectations. But those hopes were dashed when otelixizumab failed to hit the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset type 1 diabetes. Layoffs followed in March and May of this year.

Sources told FierceBiotech in October that Tolerx was officially closing up shop after spending about a decade doing R&D on drugs for immune-related disorders. Tolerx was selling off its earlier-stage assets, sources said, and GSK had taken over development of otelixizumab.

(Filing, 10-Q, Radient Pharmaceuticals, SEP 30, 2011, View Source [SID:1234506458])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!